In a related vein, Guo et al. demonstrated an increase in the percentage of CD4+ and CD8+ T cells and a decrease in the percentage of Tregs at tumour sites in a murine model of ovarian cancer as an effect of combined TIM-3 blockade and CD137 activation [97]. The gene discussed is TNFRSF9; the disease is neoplasm.